Navigation Links
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Date:3/30/2009

es on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Publication of Shire plcs Annual Report 2008
2. Shires Project Playground Gives Boost to Philadelphia
3. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. Shire Announces Opening of Office in Japan
6. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
9. Shire plc: Change to Directors Details
10. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
11. Shires New Product Portfolio Delivers Strong Quarterly Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that Lionel Goldfrank ... succeed Donald Fresne ; Mr. Fresne has also resigned ... of the Board.  In recognition of the many contributions and ... twenty years, the Board designated Mr. Fresne as Chairman Emeritus. ... Search Committee to find a suitable replacement with Biotech industry ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
(Date:12/17/2014)... Once more, EMAAR has selected BioShaft ... water treatment plant to phase one of BayLaSun, a ... years ago Bioshaft successfully supplied and operated a packaged ... towers with an occupancy of 900 residences. The ... per day and was signed on September 16th, 2014, ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... May 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ... and operational highlights for the quarter ended March 31, 2010 ... "We ... both improved our understanding of REOLYSIN(R),s mechanism of action and provided ...
... ,, CHENGDU, China , May ... ), a biopharmaceutical company that,specializes in the modernized traditional Chinese medicine ... ended March 31,2010 . , , Third ... -- Q3 FY2010 revenue increased 60% year over year ...
... Calif. , May 11 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... 9:30 a.m. Eastern Time ( 6:30 a.m. Pacific Time ).   , ... parties may access a live webcast of the presentation on our website at: , ... http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , , , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 2Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 3Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 4Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 5Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 6Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 7Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 8Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 9Tianyin Reports Record Third Quarter 2010 Financial Results 2Tianyin Reports Record Third Quarter 2010 Financial Results 3Tianyin Reports Record Third Quarter 2010 Financial Results 4Tianyin Reports Record Third Quarter 2010 Financial Results 5Tianyin Reports Record Third Quarter 2010 Financial Results 6Tianyin Reports Record Third Quarter 2010 Financial Results 7Tianyin Reports Record Third Quarter 2010 Financial Results 8Tianyin Reports Record Third Quarter 2010 Financial Results 9Tianyin Reports Record Third Quarter 2010 Financial Results 10Tianyin Reports Record Third Quarter 2010 Financial Results 11Tianyin Reports Record Third Quarter 2010 Financial Results 12Tianyin Reports Record Third Quarter 2010 Financial Results 13Onyx Pharmaceuticals to Present at the Baird 2010 Growth Stock Conference 2
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... more cost-effective, a group of researchers from National Tsing Hua ... Germany have created a DNA-based memory device that is "write-once-read-many-times" ... possible to encode information. The device, described in a paper ... of a thin film of salmon DNA that has been ...
... , If they didn,t have enough to worry about ... Asia,s rugged mountains, a population of endangered markhora majestic ... time by the Wildlife Conservation Society and partners in ... impressive corkscrew horns that can reach nearly five feet ...
... UCLA researchers have identified how a component of an ... the plant Hovenia, counteracts acute alcohol intoxication and withdrawal ... the action of alcohol on the brain and neurons ... side effects, in an early study with rats. Specifically, ...
Cached Biology News:Wildlife Conservation Society documents pneumonia outbreak in endangered markhor 2
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Criterion staining and blotting trays are plastic trays designed for staining one or two Criterion gels or performing western blot detection. The trays have a working capacity of up to 500 ml. Suppli...
... of next-generation features into a small-footprint design, ... flexible laboratory solutions. It puts every aspect ... dispensing, and integrations into a single, ... as it is efficient and economical. The ...
... Biomek FX P is the latest entry ... for greater positional accuracy and increased robustness, it ... application. It can be configured with either one ... capacity, the Biomek FX P sets the ...
Biology Products: